LightRay
Are You Eligible?This trial is testing sotatercept in adults with pulmonary arterial hypertension (PAH).
Research Objectives
Status
Recruitment
Total participants required
Study location
Study type
Patient group
About this clinical trial
PAH is a type of high blood pressure that affects arteries that go from the heart to the lungs. Sotatercept given by weight-based dosing has been approved in the US (but not yet in Australia) to treat PAH in adults. This trial aims to test the safety of Sotatercept and compare 2 different methods of dosing: “weight-based” (dose based on exact body weight) and “weight-banded” (dose based on weight bands with a different dose assigned to each band).
Eligibility
- Age 18 years or over
- Weight >35kg
- Group 1 Pulmonary Artery Hypertension
- On stable therapy for a least 90 days
Lead investigator
- Dr John Feenstra
Clinical trial coordinators
- Bronwen Field
- Chris Henderson
- Marie-Louise Oegema
Technical title
A Phase 2, Multicenter, Single-blinded, Randomized Study to Evaluate the Pharmacokinetics and Safety of Sotatercept (MK-7962) Administered Using Either a Weight-based or Weight-banded Approach in Participants With Pulmonary Arterial Hypertension (PAH) on Standard of Care
The clinical trial is closed for recruitment
If you would like more information about this clinical trial, please complete the contact form below.